Skip to content

Phase 2a study for NASH

A Double-Blind, Placebo Controlled, Single Dosing, Dose-Escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Characteristics of J2H-1702 (Nonalcoholic Steatohepatitis Treatment Candidate) after Oral Administration in Healthy Female Subjects

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CRIS
Registry ID
KCT0008007
Enrollment
16
Registered
2022-12-13
Start date
2023-01-02
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : - IP: J2H-1702 - Oral Medication - Dose - Amg, Bmg

Sponsors

J2H Biotech
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Healthy females aged = 19 and = 45 years 2) Subjects with a body mass index (BMI) = 18.0 to = 27.0 kg/m2 3) Subjects confirmed to be clinically healthy based on the medical history, physical examination, vital signs, electrocardiogram (ECG), and appropriate clinical laboratory tests 4) Agree to use dual contraceptive methods and not to donate eggs 5) Voluntarily agree to participate in the study

Exclusion criteria

Exclusion criteria: 1) A subject who had or has the disease corresponding to clinically significant liver, etc. 2) A subject with a history of gastrointestinal diseases or surgery 3) A subject who has a history of clinically significant hypersensitivity to drugs containing 11ß-HSD1 inhibitor 4) A subject who has genetic problems such as galactose intolerance, Lap galactose intolerance, Lap lactase deficiencies, or glucose ·galactose malabsorptivity, etc. 5) One who has drug abuse and one who is positive response in urine drug screening tests 6) A subject with abnormal vital signs at the screening visit 7) A subject who has participated in another clinical trial or bioequivalence test 8) A subject who donated whole blood or the ingredient, or received blood transfusion 9) A subject who took drug metabolizing enzyme-inducing and inhibitory drugs 10) A subject who consumes grapefruit/caffeine-containing food 11) A subject who took any prescription drug or herbal medicine or took any Over The Counter Drug (OTC) 12) High caffeine intaker, high alcohol intaker or excessive smoker 13) A subject who cannot eat meals provided by the Clinical Trial institution. 14) A subject who participated in this trial and were administered the investigational product. 15) A subject who is positive for serum test 16) A pregnanct or breast-feeding subject 17) A subject who the investigator deems inappropriate for this clinical trial

Design outcomes

Primary

MeasureTime frame
Vital sign, Physical exam, 12-lead ECG, Clinical laboratory tests, Drug screen and serology etc.

Secondary

MeasureTime frame
Cmax, AUClast, AUCinf, Tmax, t1/2, fe, CLR, CL/F, Vz/F;Serum cortisol- ?Emax and ?AUEClast/ 24-hour urinary free cortisol- ?Eufc

Countries

Korea, Republic of

Contacts

Public ContactSangWon Lee

Hanyang University Seoul Hospital

swlee@hyumc.com+82-2-2290-8114

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026